Literature DB >> 22684028

Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.

Sugunadevi Sakkiah1, Keun Woo Lee.   

Abstract

AIM: To identify the critical chemical features, with reliable geometric constraints, that contributes to the inhibition of butyrylcholinesterase (BChE) function.
METHODS: Ligand-based pharmacophore modeling was used to identify the critical chemical features of BChE inhibitors. The generated pharmacophore model was validated using various techniques, such as Fischer's randomization method, test set, and decoy set. The best pharmacophore model was used as a query in virtual screening to identify novel scaffolds that inhibit BChE. Compounds selected by the best hypothesis in the virtual screening were tested for drug-like properties, and molecular docking study was applied to determine the optimal orientation of the hit compounds in the BChE active site. To find the reactivity of the hit compounds, frontier orbital analysis was carried out using density functional theory.
RESULTS: Based on its correlation coefficient (0.96), root mean square (RMS) deviation (1.01), and total cost (105.72), the quantitative hypothesis Hypo1 consisting of 2 HBA, 1 Hy-Ali, and 1 Hy-Ar was selected as the best hypothesis. Thus, Hypo1 was used as a 3D query in virtual screening of the Maybridge and Chembridge databases. The hit compounds were filtered using ADMET, Lipinski's Rule of Five, and molecular docking to reduce the number of false positive results. Finally, 33 compounds were selected based on their critical interactions with the significant amino acids in BChE's active site. To confirm the inhibitors' potencies, the orbital energies, such as HOMO and LUMO, of the hit compounds and 7 training set compounds were calculated. Among the 33 hit compounds, 10 compounds with the highest HOMO values were selected, and this set was further culled to 5 compounds based on their energy gaps important for stability and energy transfer. From the overall results, 5 hit compounds were confirmed to be potential BChE inhibitors that satisfied all the pharmacophoric features in Hypo1.
CONCLUSION: This study pinpoints important chemical features with geometric constraints that contribute to the inhibition of BChE activity. Five compounds are selected as the best hit BchE-inhibitory compounds.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684028      PMCID: PMC4077067          DOI: 10.1038/aps.2012.21

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  40 in total

Review 1.  Pharmacogenetics, drug-metabolizing enzymes, and clinical practice.

Authors:  Sharon J Gardiner; Evan J Begg
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase.

Authors:  Asim Kumar Debnath
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

3.  3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.

Authors:  Sugunadevi Sakkiah; Sundarapandian Thangapandian; Shalini John; Yong Jung Kwon; Keun Woo Lee
Journal:  Eur J Med Chem       Date:  2010-02-04       Impact factor: 6.514

Review 4.  Cholinesterases: new roles in brain function and in Alzheimer's disease.

Authors:  Ezio Giacobini
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 5.  The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5'butyrylcholinesterase-DNA study.

Authors:  A Mack; A Robitzki
Journal:  Prog Neurobiol       Date:  2000-04       Impact factor: 11.685

6.  Butyrylcholinesterase formulated in liposomes.

Authors:  I Schumacher; A Arad; R Margalit
Journal:  Biotechnol Appl Biochem       Date:  1999-12       Impact factor: 2.431

7.  Selective inhibition of carboxylesterases by isatins, indole-2,3-diones.

Authors:  Janice L Hyatt; Teri Moak; M Jason Hatfield; Lyudmila Tsurkan; Carol C Edwards; Monika Wierdl; Mary K Danks; Randy M Wadkins; Philip M Potter
Journal:  J Med Chem       Date:  2007-03-23       Impact factor: 7.446

8.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

Authors:  Bin Li; Meghan Sedlacek; Indumathi Manoharan; Rathnam Boopathy; Ellen G Duysen; Patrick Masson; Oksana Lockridge
Journal:  Biochem Pharmacol       Date:  2005-10-06       Impact factor: 5.858

Review 9.  Structure and functions of acetylcholinesterase and butyrylcholinesterase.

Authors:  J Massoulié; J Sussman; S Bon; I Silman
Journal:  Prog Brain Res       Date:  1993       Impact factor: 2.453

10.  4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields.

Authors:  Maja D Vitorović-Todorović; Ivan O Juranić; Ljuba M Mandić; Branko J Drakulić
Journal:  Bioorg Med Chem       Date:  2009-12-22       Impact factor: 3.641

View more
  15 in total

1.  Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.

Authors:  Vivek Kumar Singh; Mohane Selvaraj Coumar
Journal:  J Mol Model       Date:  2017-07-01       Impact factor: 1.810

2.  Potential acetylcholinesterase inhibitors: molecular docking, molecular dynamics, and in silico prediction.

Authors:  Alessandra S Kiametis; Mônica A Silva; Luiz A S Romeiro; João B L Martins; Ricardo Gargano
Journal:  J Mol Model       Date:  2017-02-09       Impact factor: 1.810

3.  Computer-aided identification of lead compounds as Staphylococcal epidermidis FtsZ inhibitors using molecular docking, virtual screening, DFT analysis, and molecular dynamic simulation.

Authors:  Swayansiddha Tripathy; Susanta Kumar Sahu; Mohammed Afzal Azam; Srikanth Jupudi
Journal:  J Mol Model       Date:  2019-11-26       Impact factor: 1.810

4.  3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors.

Authors:  Vikas Kumar; Shraddha Parate; Amir Zeb; Pooja Singh; Gihwan Lee; Tae Sung Jung; Keun Woo Lee; Min Woo Ha
Journal:  Front Cell Infect Microbiol       Date:  2022-06-30       Impact factor: 6.073

5.  Modeling in vitro inhibition of butyrylcholinesterase using molecular docking, multi-linear regression and artificial neural network approaches.

Authors:  Fang Zheng; Max Zhan; Xiaoqin Huang; Mohamed Diwan M Abdul Hameed; Chang-Guo Zhan
Journal:  Bioorg Med Chem       Date:  2013-11-08       Impact factor: 3.641

6.  Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.

Authors:  Raj Kumar; Minky Son; Rohit Bavi; Yuno Lee; Chanin Park; Venkatesh Arulalapperumal; Guang Ping Cao; Hyong-ha Kim; Jung-keun Suh; Yong-seong Kim; Yong Jung Kwon; Keun Woo Lee
Journal:  Acta Pharmacol Sin       Date:  2015-06-08       Impact factor: 6.150

7.  Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.

Authors:  Yi-Yu Ke; Vivek Kumar Singh; Mohane Selvaraj Coumar; Yung Chang Hsu; Wen-Chieh Wang; Jen-Shin Song; Chun-Hwa Chen; Wen-Hsing Lin; Szu-Huei Wu; John T A Hsu; Chuan Shih; Hsing-Pang Hsieh
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

8.  Virtual Screening and Statistical Analysis in the Design of New Caffeine Analogues Molecules with Potential Epithelial Anticancer Activity.

Authors:  Josivan da Silva Costa; Karina da Silva Lopes Costa; Josiane Viana Cruz; Ryan da Silva Ramos; Luciane Barros Silva; Davi Do Socorro Barros Brasil; Carlos Henrique Tomich de Paula da Silva; Cleydson Breno Rodrigues Dos Santos; Williams Jorge da Cruz Macedo
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

9.  Cinnamaldehyde, Cinnamic Acid, and Cinnamyl Alcohol, the Bioactives of Cinnamomum cassia Exhibit HDAC8 Inhibitory Activity: An In vitro and In silico Study.

Authors:  Mangesh Patil; Amit S Choudhari; Savita Pandita; Md Ataul Islam; Prerna Raina; Ruchika Kaul-Ghanekar
Journal:  Pharmacogn Mag       Date:  2017-10-11       Impact factor: 1.085

10.  In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors.

Authors:  Simone Brogi; Simone Giovani; Margherita Brindisi; Sandra Gemma; Ettore Novellino; Giuseppe Campiani; Michael J Blackman; Stefania Butini
Journal:  J Mol Graph Model       Date:  2016-01-19       Impact factor: 2.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.